+Advanced Search
Home > Archive>Volume 26, Issue 5, 2016 >19-24. DOI:10.3969.j.issn.1671-7856. 2016.005.003
PDF HTML XML Export Cite reminder
Effect of Slit2 on nonalcoholic fatty liver disease
Author:
  • Article
    • | |
  • Metrics
    • |
  • Reference [23]
    • | | | |
  • Comments
    Abstract:

    Objective To investigate the effect of Slit2 over-expression on nonalcoholic fatty liver disease (NAFLD) in mice. Methods Eight week male LDLR-/- mouse and LDLR-/-;Slit2-Tg mouse were fed a high-fat diet for 12 weeks to induce NAFLD(n=6 per group). After 12 weeks, they were taken for blood samples and dissected. The concentration of TG (triglycerides), TC(total cholesterol), LDL-C(low density lipoprotein cholesterol) and HDL-C(high density lipoprotein cholesterol)in the serum were examined respectively. Liver tissue samples were taken for HE staining to observe the morphological and pathological changes. The mRNA expression levels of hepatic genes related to lipid metabolism such as LXR-α,LXR-β FAS,SREBP-1c was measured by real-time RT-PCR. Results The serum LDL-C levels of LDLR-/-;Slit2-Tg mouse were significantly lower than that in LDLR-/- mouse(P < 0.01).And the grade of lipid droplets and pathological injury of liver tissue decreased significantly in the LDLR-/-;Slit2-Tg mouse compared with LDLR-/- mouse. Furthermore, The mRNA expression levels of hepatic genes related to lipid metabolism decreased significantly in the LDLR-/-;Slit2-Tg mouse. Conclusions The overexpression of Slit2 can reduce the pathological injury of liver tissue in mouse with NAFLD.

    Reference
    [1] Angulo P. Nonalcoholic fatty liver disease[J].N Engl J Med, 2002,346(16): 1221-1231.
    [2] Shen L, Fan JG, Shao Y, et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey[J].World J Gastroenterol,2003,9(5):1106-1110.
    [3] Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther,2011,34(3):274–285.
    [4] Caldwell S,Argo C. The natural history of non-alcoholic fatty liver disease [J].Dig Dis,2010,28(1):162-168.
    [5] Li HS, Chen JH, Wu W, et al. Vertebrate slit, a secreted ligand for the transmembrane protein roundabout,is a repellent for olfactory bulb axons[J].Cell,1999,96(6):807-818.
    [6] Chedotal A.Slits and their receptors[J].Adv Exp Med Biol,2007,621:65-80.
    [7] Dickinson RE, Duncan WC. The SLIT-ROBO pathway: a regulator of cell function with implications for the reproductive system[J].Reproduction,2010, 139(4):697-704.
    [8] Jianlan Chang, Tian Lan, Changzheng Li, et al. Activation of Slit2-Robo1 signaling promotes liver fibrosis[J].Journal of Hepatology,2015,63(6): 1413-1420.
    [9] Han HX,Geng JG.Over-expression of Slit2 induces vessel formation and changes blood vessel permeability in mouse brain[J].Acta Pharmacol Sinica,2011,32(11):1327-1336.
    [10] Inzucchi SE, Petersen KF, Shulman GI. Nonalcoholic fatty liver disease[J]. N Engl J Med,2002,347(10):768-769.
    [11] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther,2011,34(3):274-285.
    [12] Sharabi M, Eldad A. Nonalcoholic fatty liver disease is associated with hyperlipidemia and obesity[J].Am J Med,2000,109(2):171.
    [13] Takahashi Y, Sugimoto K, Inui H, et al. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].World J Gastroenterol,2015,21(13):3777-3785.
    [14] Polyzos SA, Kountouras J, Zavos C.Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines[J].Curr Mol Med,2009,9(3):299-314.
    [15] Day CP.Non-alcoholic fatty liver disease: a massive problem[J].Clin Med, 2011,11(2):176-178.
    [16] Higuchi N, Kato M, Shundo Y, et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease[J].Hepatol Res,2008,38(11):1122-1129.
    [17] Mehmet Ender Avci,Ozlen Konu,Tamer Yagci,et al. Quantification of SLIT-ROBO transcripts in hepatocellular carcinoma reveals two groups of genes with coordinate expression[J].BMC Cancer,2008,8(1):1-11.
    [18] Wang B, Xiao Y, Ding BB, et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity[J].Cancer Cell,2003,4(1):19-29.
    [19] Barrett PH, Watts GF. Shifting the LDL-receptor paradigm in familial hypercholesterolemia: novel insights from recent kinetic studies of apolipoprotein B-100 metabolism[J].Atheroscler Suppl,2002,2(3):1-4.
    [20] Chen G, Liang G, Ou J, et al. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver[J].Proc Natl Acad Sci U S A,2004,101(31): 11245-11250.
    [21] Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis[J].Genes Dev,2000,14(22):2831-2838.
    [22] Ferre P, Foufelle F.SREBP-1c transcription factor and lipid homeostasis: clinical perspective[J].Horm Res,2007,68(2):72-82.
    [23] Repa JJ, Liang G, Ou J, et al. Regulation of mouse sterol regulatory element- binding protein-1c gene(SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta[J].Genes Dev,2000,14(22):2819-2830.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Copy
Share
Article Metrics
  • Abstract:2213
  • PDF: 1589
  • HTML: 0
  • Cited by: 0
History
  • Revised:February 25,2016
  • Online: June 01,2016
Article QR Code
You are the first3048852 Visitors
® 2025 All Rights Reserved
Address：5 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China Postcode： Phone：86-10-67779337 E-mail:bjb@cnilas.org
Supported by:Beijing E-Tiller Technology Development Co., Ltd.